End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
62.63 CNY | +0.69% | -1.99% | -6.42% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
Weaknesses
- With an expected P/E ratio at 35.59 and 26.68 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 4.2 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.42% | 4.12B | C | ||
-1.12% | 89.37B | A- | ||
+2.76% | 40.65B | A- | ||
-12.32% | 32.81B | B- | ||
+52.41% | 25B | A | ||
-17.39% | 15.29B | C | ||
-42.45% | 11.61B | B | ||
-10.48% | 11.49B | D+ | ||
+6.14% | 8.98B | B+ | ||
-7.72% | 8.23B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 688363 Stock
- Ratings Bloomage BioTechnology Corporation Limited